Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | LATS1 | O95835 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524909 | 0.81 | KDR (0.80) | KDRRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL6328806 | 0.78 | KDR (0.71) | KDRRAB9ANPC1SMN1; SMN2ABL1 | |
| SCHEMBL6330404 | 0.78 | KDR (1.00) | KDRLIMK1NAMPT | |
| SCHEMBL1884904 | 0.77 | MAPT (0.64) | RAB9AHDAC6MEN1KMT2AMAPT | |
| SCHEMBL4601487 | 0.77 | RAB9A (0.62) | KDRRAB9AHDAC6MEN1KMT2A | |
| SCHEMBL996232 | 0.76 | RAB9A (1.00) | RAB9AHDAC6MEN1KMT2AMAPT | |
| SCHEMBL6181301 | 0.75 | KDR (0.82) | KDRRAB9AMEN1KMT2AMAPT | |
| SCHEMBL3651635 | 0.74 | KDR (1.00) | KDRNAMPT | |
| SCHEMBL10569930 | 0.73 | NPSR1 (0.70) | KDRRAB9AHDAC6MEN1KMT2A | |
| SCHEMBL5889064 | 0.73 | KIT (0.62) | KDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-12448437-B2 | Transplant tolerance induction with carbodiimide treated tolerizing vaccine | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025215206-A1 | ACTIVATOR OF PRIMARY CILIA TO TREAT COGNITIVE DYSFUNCTIONS OR CILIOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-10-16 | — | — | WO | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4417212-A2 | TRANSPLANT TOLERANCE INDUCTION WITH CARBODIIMIDE TREATED TOLERIZING VACCINE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240145038-A1 | cfDNA FRAGMENTOMIC DETECTION OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2016144569-A1 | METHODS AND COMPOSITIONS FOR TREATING SKIN TO RESOLVE INFLAMMATION AND SCREENING FOR ACTIVES THAT STIMULATE PRO-RESOLUTION PATHWAYS | ELC MANAGEMENT LLC (US) | 2016-09-15 | — | — | WO | disclosed |
| EP-2941241-A1 | METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS AND VIABILITY IN CELLS OF KERATIN SURFACES | ELC Management LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-20150313830-A1 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces | ELC MAN LLC (US) | 2015-11-05 | — | — | US | disclosed |
| CN-104902872-A | Methods and compositions for improving selective catabolism and viability in cells on the surface of keratin | ELC MAN LLC | 2015-09-09 | — | — | CN | disclosed |
| EP-2897582-A1 | METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS IN CELLS OF KERATIN SURFACES | ELC Management LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| CN-104797237-A | Methods and compositions for improving selective catabolism in cells on the surface of keratin | ELC MAN LLC | 2015-07-22 | — | — | CN | disclosed |
| US-20150071895-A1 | Method And Compositions For Improving Selective Catabolysis in Cells Of Keratin Surfaces | PERNODET NADINE A (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140193391-A1 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces | ELC MAN LLC (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014107411-A1 | METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS AND VIABILITY IN CELLS OF KERATIN SURFACES | ELC MANAGEMENT LLC (US) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014043009-A1 | METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS IN CELLS OF KERATIN SURFACES | ELC MANAGEMENT LLC (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313830-A1 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces | KRT18, CTSA, UNG | KDR 2309/4885RAB9A 2161/4885HDAC6 217/4885 |
| US-20150071895-A1 | Method And Compositions For Improving Selective Catabolysis in Cells Of Keratin Surfaces | KRT18, ATG7, SQSTM1 | KDR 3123/4885RAB9A 2364/4885HDAC6 80/4885 |
| US-20140193391-A1 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces | KRT18, BECN1, CTSA | KDR 2326/4885RAB9A 3292/4885HDAC6 105/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | KDR 45/4885RAB9A 1443/4885HDAC6 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.